Cover image for FDA Decisions Expected: November 2024 Drug pipeline for November 2024 Prime Therapeutics /fda-decisions-expected-november-2024 Prime Therapeutics’ FDA Decisions Expected outlines...

Commercial information Your Choices Regarding Your Information You may have the following rights with respect to your personal information, subject to applicable exceptions: Right to access. You...

Home Newsroom Custom Content Publications High Cost Therapy Profile High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel Intravenous (IV) Autolus Proposed...

A female-presenting person speaks at a legislative building, wearing a green blazer and glasses. George Van Antwerp breaks down how Prime is poised to drive affordability in drug pricing Alex Cook...

These new solutions reflect Prime's distinctive conflict-free approach to the prescription drug supply chain model.

Pharmacy Friends In the latest episode of the “Pharmacy Friends” podcast, learn the latest insights on legislative trends, cutting-edge drug therapies and more from the 22nd annual event Alex Cook...

New Biosimilars First Generic Drug Launches Oct. 25, 2024 - sulopenem etzadroxil and probenecid (Orlynvah) The FDA has approved Iterum’s Orlynvah for the treatment of uncomplicated urinary tract...

Upgrade provides streamlined patient support and enhanced digital engagement for data-driven, holistic care

FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...

Based on the clinical trial, there are certain expectations for how long patients can anticipate seeing the benefits of treatment. The median duration of response was 11.6 months (95% CI, 4.4 to...